title: [A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin].
abstract: Theophylline toxicity has been recognized since its introduction into clinical medicine. Clarithromycin is a new oral macrolide antibiotic with excellent antibacterial activity and rare adverse effect. Patients with upper respiratory infection are often treated with theophylline and clarithromycin concurrently. We report a case of acute renal failure due to acute rhabdomyolysis caused by the interaction of theophylline and clarithromycin. A 72-year-old man visited our hospital because of coughing and a sore throat continuing for 1 week. He was diagnosed as having the common cold with a bronchial asthmatic symptom and was prescribed 200 mg/day of sustained-release theophylline for the treatment of asthma for 7 days. One week later, he visited our hospital again. Radiographic study of the chest revealed mild interstitial pneumonia and 200 mg/day of sustained-release theophylline and 400 mg/day of clarithromycin were administrated concomitantly. Five days after the second visit, the patient was admitted to our hospital because of generalized twitching, muscular weakness, high fever and serious general condition. He experienced generalized muscular twitching and tremor. Blood urea nitrogen was 106.1 mg/dl, serum creatinine was 7.4 mg/dl, serum creatinine kinase (CK) was 36,000 IU/l (normal 15-130 IU/l), CK isozyme revealed the following ratio: BB 0%, MB 1% and MM 99%. He was diagnosed as having acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin. Hemodialysis therapy was started. After 5 weeks, his serum creatinine was markedly decreased. It is well-known that clarithromycin enhances the serum concentration of theophylline by inhibition of the cytochrome P450-dependent pathway in hepatocytes. Theophylline toxicity may be enhanced when clarithromycin is administrated concomitantly, especially to elderly patients with dehydration.
authors.affiliation: Department of Medicine, Koto Hospital, Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Shimada
authors.forename: H
authors.initials: H
authors.lastname: Omuro
authors.forename: S
authors.initials: S
authors.lastname: Saka
authors.forename: I
authors.initials: I
authors.lastname: Ebihara
authors.forename: H
authors.initials: H
authors.lastname: Koide
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001993:Bronchodilator Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D017291:Clarithromycin / Q000009:adverse effects*; D065607:Cytochrome P-450 Enzyme Inhibitors; D003692:Delayed-Action Preparations; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D008099:Liver / Q000201:enzymology; D008297:Male; D012206:Rhabdomyolysis / Q000139:chemically induced*; D013806:Theophylline / Q000009:adverse effects* / Q000493:pharmacokinetics
chemical_list: D000900:Anti-Bacterial Agents; D001993:Bronchodilator Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D003692:Delayed-Action Preparations; D013806:Theophylline; D017291:Clarithromycin